Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gene Therapy Manufacturing Remains Large Hurdle For Development, US FDA's CBER Director Says

Mar 09 2018

• By Derrick Gingery

T-cells attacking cancer_1200x675

Related Content

How To Build An Endpoint: Spark Designed Testing Maze To Study Rare Vision Loss

Oct 15 2017

Spark's Early Christmas Present: US FDA Approves Luxturna For Vision Loss

Dec 19 2017

Capacity Shortages Unlikely To Hold Back Cell And Gene Therapies

Dec 12 2017

Gene Therapies: Safety, CMC Draft Guidances Coming From US FDA In 2018

Jan 24 2018

RMAT Designation, Gene Therapies Highlight 2017 CBER Transformation

Jan 18 2018

FDA Highlights Advanced Drug Manufacturing Approaches In Budget Plan

Feb 13 2018

US FDA/NORD Partnership Will Further Increase Patient Involvement In Drug Development

Feb 28 2018

Related Companies

Spark Therapeutics, Inc.

Novartis AG

Kite Pharma, Inc.

Additional Topics

United States Regenerative Medicine Manufacturing FDA BioPharmaceutical

More from Cell & Gene Therapies

More from Advanced Technologies

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window